Demographics of Patients Receiving Tecovirimat (TPOXX) for Treatment of Mpox

Mpox Archive Content

You are viewing an archived web page, collected from CDC’s Mpox website. The information on this web page may be out of date.

CDC holds an expanded access Investigational New Drug (EA-IND) protocol for use of tecovirimat (TPOXX) for treatment of mpox. The IND forms are required to be submitted to CDC. The demographics of patients prescribed tecovirimat treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who received tecovirimat during the 2022 mpox outbreak as healthcare providers were allowed to start treatment before submitting IND paperwork to CDC.

These data may not reflect the overall population of patients who have been prescribed tecovirimat since CDC did not receive forms for every patient treated with tecovirimat. Some sections of the submitted forms had missing values.